Lag Time Between Evidence and Guidelines: Can Clinical Pathways Bridge the Gap?

Area of Science:

• Radiation Oncology
• Breast Cancer Treatment
• Clinical Pathways

Background:

• Hypofractionated whole-breast irradiation (HF-WBI) is recommended for early-stage breast cancer regardless of age per 2018 guidelines.
• Evidence supporting HF-WBI for younger patients predates guideline publication.
• Practice patterns often lag behind emerging clinical evidence.

Purpose of the Study:

• To evaluate the impact of clinical pathway implementation on HF-WBI adoption in women under 50.
• To accelerate the integration of evidence-based HF-WBI into clinical practice.
• To standardize care within a comprehensive radiation oncology network.

Main Methods:

• A breast cancer clinical pathway was amended to promote HF-WBI use in women under 50.
• The pathway was initially updated to allow HF-WBI, then mandated it as the sole option.
• Patient data (stage 0-IIA, no regional node irradiation) were analyzed using logistic regression.

Main Results:

• HF-WBI use increased from 4.2% to 96.5% after pathway amendments.
• Initial disparities in HF-WBI use between academic and community sites were resolved after the second amendment.
• The mandated pathway led to rapid and widespread adoption of HF-WBI.

Conclusions:

• Mandatory clinical pathways can rapidly increase the adoption of evidence-based treatments like HF-WBI.
• Clinical pathways effectively standardize care, aligning practice with current evidence.
• This approach standardizes care independently of formal guideline updates.